血小板
血清素
血小板活化
纤维蛋白
肺
呼吸系统
免疫学
医学
免疫系统
呼吸道疾病
疾病
病理
封锁
生物
作者
Davide Marotta,Chiara Perucchini,Marta Grillo,Valeria Fumagalli,Pietro Di Lucia,Jordan A. Rixon,Micol Ravà,Leonardo Giustini,Chiara Malpighi,Giulia D’Uonnolo,Mariangela Scavone,Violette Mouro,Caitlin A. Abbott,Natalia Stachura-Chyla,Francesco Andreata,Erica Scalambrino,Marigrazia Clerici,Lorena Donnici,Marika Longo Minnolo,Donato Inverso
出处
期刊:Science immunology
[American Association for the Advancement of Science]
日期:2026-08-28
卷期号:11 (122): eaec9853-eaec9853
标识
DOI:10.1126/sciimmunol.aec9853
摘要
Elderly individuals affected by COVID-19 are vulnerable to severe respiratory failure for reasons that have remained poorly defined. Here, we show that platelet-released serotonin drives lung pathology in a mouse model of age-associated disease severity after SARS-CoV-2 infection. In middle-aged mice and aged human healthy donors, platelet serotonin release upon activation was enhanced, and increased morbidity with respiratory dysfunction was associated with activated platelets aggregating and promoting fibrin deposition in the lung microvasculature. Pharmacologic or genetic disruption of serotonin uptake, or blockade of serotonin-dependent signaling, attenuated platelet activation and protected against respiratory distress, independently of viral replication and immune responses. Inhibition of fibrin formation similarly reduced disease severity, implicating serotonin-driven platelet procoagulant activity as a key contributor to age-related lung dysfunction. Thus, serotonin-mediated platelet procoagulant activity is a major contributor to respiratory insufficiency during SARS-CoV-2 infection and a potential therapeutic target for preserving pulmonary function, particularly in the elderly.
科研通智能强力驱动
Strongly Powered by AbleSci AI